In vivo emergence of resistance to ceftazidime/avibactam through modification of chromosomal AmpC β-lactamase in Klebsiella aerogenes

Salud Rodríguez-Pallares,Tania Blanco-Martín,Emilio Lence,Pablo Aja-Macaya,Lucía Sánchez-Peña,Lucía González-Pinto,María Rodríguez-Mayo,Ana Fernández-González,Fátima Galán-Sánchez,Alejandro Beceiro,Concepción González-Bello,Germán Bou,Jorge Arca-Suárez
DOI: https://doi.org/10.1128/aac.01307-24
IF: 5.938
2024-11-07
Antimicrobial Agents and Chemotherapy
Abstract:ABSTRACT We describe the in vivo emergence of resistance to ceftazidime/avibactam via modification of AmpC in a clinical Klebsiella aerogenes isolate during therapy with this combination. Paired ceftazidime/avibactam-susceptible/resistant isolates were obtained before and during ceftazidime/avibactam treatment. Whole genome sequencing revealed a differential mutation in AmpC (R148W) in the ceftazidime/avibactam-resistant isolate. Molecular cloning and structural studies confirmed the impact of this substitution, which affects the architecture of the H10 helix, on the evolved resistant phenotype.
pharmacology & pharmacy,microbiology
What problem does this paper attempt to address?